Clinical trial · Interventional
First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
A Randomized, Open-label Phase II Study of Pemetrexed (Alimta) Plus Carboplatin With or Without Enzastaurin Hydrochloride, or Docetaxel Plus Carboplatin as First Line Treatment in Patients With Advanced Stage Non-small Cell Lung Cancer (NSCLC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purposes of this study are to determine: The safety of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin, or docetaxel with carboplatin and any side effects that might be associated with the combination of these drugs. Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can help participants with non-small cell lung cancer (NSCLC) live longer, compared with the combination of docetaxel and carboplatin. Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can make your tumor smaller or disappear, and for how long, compared with the combination of docetaxel and carboplatin. The effects of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin or docetaxel with carboplatin have on your disease related symptoms. The relation of smoking history and hormone replacement therapy (for women only) may have to your lung cancer treatment results. The effects of certain genes and proteins in samples of your blood and tumor tissue in order to learn more about NSCLC and how enzastaurin works in the body.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin | Drug | Carboplatin | ALIAS |
| docetaxel | Drug | Docetaxel | ALIAS |
| enzastaurin | Drug | Enzastaurin | ALIAS |
| pemetrexed | Drug | Pemetrexed | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Enzastaurin/Pemetrexed/Carboplatin
- interventionNames
- Drug: enzastaurin
- Drug: pemetrexed
- Drug: carboplatin
- type
- EXPERIMENTAL
- label
- Pemetrexed/Carboplatin
- interventionNames
- Drug: pemetrexed
- Drug: carboplatin
- type
- ACTIVE_COMPARATOR
- label
- Docetaxel/Carboplatin
- interventionNames
- Drug: docetaxel
- Drug: carboplatin
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * You must have been diagnosed with NSCLC. * You must be able to visit the doctor's office weekly during the active treatment period and as needed during the study follow-up period. * You must be willing and able to swallow capsules. * Your entry labs and medical tests must meet study requirements. * You must be willing to have blood samples drawn and tissue samples obtained for gene and protein testing. Exclusion Criteria: * You have received radiation within 2 weeks of study enrollment. * You have previously received any anti-cancer drug therapy for NSCLC. * You have an active infection or other serious condition. * You take aspirin or aspirin-like medication regularly and are not able to stop taking them for a few days during each cycle of chemotherapy. * You have recently lost a significant amount of weight.
References
Publications (1)
- DERIVEDSocinski MA, Raju RN, Stinchcombe T, Kocs DM, Couch LS, Barrera D, Rousey SR, Choksi JK, Jotte R, Patt DA, Periman PO, Schlossberg HR, Weissman CH, Wang Y, Asmar L, Pritchard S, Bromund J, Peng G, Treat J, Obasaju CK. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol. 2010 Dec;5(12):1963-9. doi: 10.1097/JTO.0b013e3181fd42eb. PMID 21102260